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Abstract
Title of Dissertation: FUNCTION OF INSULIN-LIKE GROWTH FACTOR
BINDING PROTEIN 7(IGFBP7) IN HEPATOCELLULAR CARCINOMA By Dong
Chen.
Purpose: Hepatocellular carcinoma (HCC) is a highly virulent malignancy
with no effective treatment, thus requiring the development of innovative and
effective targeted therapies. The oncogene Astrocyte Elevated Gene-1 (AEG-1)
plays a seminal role in hepatocarcinogenesis and profoundly downregulates
Insulin-like Growth Factor Binding Protein-7 (IGFBP7). The present study
focuses on analyzing potential tumor suppressor functions of IGFBP7 in HCC
and the relevance of IGFBP7 downregulation in mediating AEG-1 function.
Experimental Design: IGFBP7 expression was detected by
immunohistochemistry in HCC tissue microarrays by real-time PCR and ELISA in
human HCC cell lines. Dual Fluorescence in situ hybridization was performed to
detect loss of heterozygosity at the IGFBP7 locus. Stable IGFBP7overexpressing clones were established in the background of AEG-1overexpressing human HCC cells and were analyzed for in vitro proliferation,
senescence, in vivo tumorigenesis and angiogenesis. HCC cell lines infected
with an adenovirus expressing IGFBP7 (Ad.IGFBP7) were analyzed by using in
vitro cell cycle, apoptosis, in vivo tumorigenesis assays.
Results: IGFBP7 expression is significantly downregulated in both human
HCC patients’ samples and cell lines compared to normal liver and hepatocytes.
IGFBP7 expression was also found to inversely correlate with the stages and

grade of HCC. Genomic deletion of IGFBP7 was identified in 26% of HCC
patients. Forced overexpression of IGFBP7 in AEG-1 overexpressing HCC cells
inhibited in vitro growth and induced senescence. When injected into nude mice,
in vivo growth was profoundly suppressed, potentially as a result of inhibition of
both angiogenesis and IGF1R activation by IGFBP7. Ad.IGFBP7 profoundly
inhibited viability and induced apoptosis in multiple human HCC cell lines by
inducing Reactive Oxygen Species (ROS) and activating a DNA damage
response. N-acetylcysteine could neutralize ROS and rescue the cells from
apoptosis. In early phase after Ad.IGFBP7 infection, activation of cell cycle
control proteins like Rb, p53, ATM, ATR, CHK1 and CHK2 were identified and
G2/M cell cycle arrest was recorded by FACS. Ad.IGFBP7 infection resulted in
the activation of p38 MAPK, and a p38 MAPK inhibitor SB 203580 could block
the apoptotic process. In orthotopic xenograft models of human HCC in athymic
nude mice, intravenous administration of Ad.IGFBP7 profoundly inhibited primary
tumor growth and intra-hepatic metastasis. In a nude mouse subcutaneous
model, xenografts from human HCC cells were established in both flanks and
only left- side tumors received intratumoral injection of Ad.IGFBP7. Ad.IGFBP7
markedly inhibit growth of both left-sided injected tumors and right-sided uninjected tumors by profound suppression of angiogenesis.
Conclusion: The present findings provide evidence that IGFBP7 functions as a
novel putative tumor suppressor for HCC and establish the corollary that IGFBP7
downregulation can effectively modify AEG-1 function. Targeted overexpression
of IGFBP7 may be a potential novel and effective therapy for HCC.
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Introduction

Hepatocellular carcinoma (HCC) is among the five most common neoplasms
world-wide with virtually no effective treatment for the advanced disease (1). This
dire situation mandates better understanding of the molecular mechanism of
hepatocarcinogenesis so that new targets might be identified for designing
effective therapeutic intervention. Recent studies have emphasized the
importance of the oncogene Astrocyte Elevated Gene-1 (AEG-1) in tumor
initiation, progression, angiogenesis and metastasis in diverse cancer including
HCC. In HCC specifically AEG-1 is overexpressed in >90% of patients (2, 3).
Overexpression and knock-down studies have established a fundamental role of
AEG-1 in the development and progression of HCC (3-5). AEG-1 exerts its
pleiotrophic tumorigenic effects by strongly modulating diverse intracellular
signaling pathways as well as transcriptome and proteome profiles (3, 5-7).
Microarray studies identified a plethora of AEG-1-modulated genes associated
with growth,

invasion, angiogenesis, metastasis,

senescence

and

chemoresistance (3, 6). In HCC cells, the most robustly AEG-1-downregulated
gene was insulin-like growth factor binding protein-7 (IGFBP7) (3). IGFBP7, also
known as mac25 or IGFBP-related protein-1 (IGFBP-rP1), is a secreted protein
belonging to the IGFBP family (8, 9). IGFBPs regulate the bioavailability of IGFs
by binding to IGFs with high affinity thereby limiting IGF access to IGF-IR and
inhibiting IGF activity (8, 10). However, IGFBPs also exert IGF-independent

actions. IGFBP7 differs from the other six members of this family in that it lacks
the C-terminus and have 100 times lower affinity for IGF-I (9). IGFBP7 is the only
member of IGFBP family able to bind insulin (11) and proposed to be a tumor
suppressor protein for a variety of cancers. In breast cancer, there is a loss of
heterozygosity at IGFBP7 locus in chromosome 4q, which is also a putative
tumor suppressor locus in a variety of cancers including HCC (12). While normal
tissues express abundant IGFBP7, no or very weak IGFBP7 expression is
detected in breast cancers, especially in the advanced stages (13). In breast
cancers, low IGFBP7 denotes poor prognosis in ER negative invasive cases (13,
16). Low levels of IGFBP7 were also detected in prostate and colorectal cancers
(14, 15). Interestingly, IGFBP7 expression is induced in senescent breast and
prostate epithelial cells and IGFBP7 mediates oncogenic BRAF-induced
senescence (17, 18). IGFBP7 is regarded as a senescence marker in lung,
mesothelioma, pilocytic astrocytomas and melanoma as well (18, 19, 20, 21).
The IGFBP7 level is downregulated in Cisplatin-resistant lung cancer and it is
used as a biomarker for prognosis and predicting outcome (19, 22). Increased
level of IGFBP7 is involved in the keratinocyte differention and apoptosis (23).
Overexpression of IGFBP7 results in G1 arrest and senescence in prostate
cancer cells and inhibits growth of xenografts of human prostate, bladder, breast
and colorectal cancers in nude mice (24-27). Additionally, IGFBP7 inhibits
vascular endothelial growth factor (VEGF)-induced angiogenesis (28). IGFBP7 is
regulated by p53 and deactivated by DNA methylation in lung cancer (19) and
IGFBP7 mRNA is the direct target of hsa-miRNA 124 in cervical cancer (11). In
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the present manuscript, we explore the role of IGFBP7 in HCC development and
progression. We document that IGFBP7 expression gradually decreases with the
stages and grades of HCC and a significant proportion of HCC patients harbor
IGFBP7 gene deletion. Over-expression of IGFBP7 significantly inhibited growth,
induced cell cycle arrest and apoptosis of human HCC cells both in vitro and in
vivo. These findings identify IGFBP7 as a novel putative tumor suppressor for
HCC.
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Materials and Methods

Plasmids, cell lines, culture condition, viability assays and chemical
reagents: IGFBP7 (NM_001553) human cDNA clone was obtained from Origene
Technologies, Inc (Rockville, MD) and cloned into pcDNA3.1(+)-zeo plasmid
(Invitrogen). THLE-3 cells, normal human hepatocytes immortalized by SV40 T/t
Ag, and human HCC cell lines, Hep3B, SK-Hep1 and FOCUS were obtained
from the American Type Culture Collection (Manassas, VA) and were cultured
according to the instructions (3). Human HCC cell lines HepG3 and Huh7 were
kindly provided by Dr. Paul Dent and were cultured as described (3). Generation
of Hep-AEG-1-8, Hep-AEG-1-14 and Hep-AEG-1-20 clones, HepG3 cells stably
expressing AEG-1, and Hep-pc-4, HepG3 cells stably transduced with empty
vector, was as described (3). Hep-AEG-1-14 cells were stably transduced with
IGFBP7 expression vector using lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. The cells were then selected for 2 weeks in 200 µg/ml
zeocin and individual colonies were isolated. Control zeocin-resistant clones of
Hep-AEG-1-14 cells were similarly generated by transfection with empty
pcDNA3.1(+)-zeo vector. Cell viability was determined by standard MTT assay as
described (3). For colony formation assays, cells (500) were plated in 6-cm
dishes and colonies of greater than 50 cells were counted after 2 weeks.
Patient samples and Tissue microarray (TMA): Patient samples were
obtained from the Liver Tissue Cell Distribution System (LTCDS) (NIH contract
#N01-DK-7-0004 / HHSN267200700004C). The 18 matched normal liver and
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HCC samples include LTCDS # 1100, 1107, 1135, 1143, 1153, 1154, 1164,
1169, 1172, 1174, 1194, 1216, 1237, 1246, 1260, 1264, 1276 and 1282. Two
human HCC TMAs (Imgenex; IMH-360 and IMH-318), including 9 normal
adjacent liver samples, were used for immunohistochemistry.
Fluorescence in situ hybridization (FISH): Dual color FISH was
performed as described on HCC TMAs (23). Bacterial artificial chromosome
(BAC)-derived test probe targeting IGFBP7 (4q12, RP11-313C13; BACPAC
Resources Center) was labeled with Spectrum Orange; this was paired for dualtarget hybridization with control probe CEP4 (probe targeting centromeric region
of chromosome 4; Abbott Laboratories, Abbott Park, Illinois). The CEP4 probe
provided enumeration of chromosome copy number for chromosome 4. Sections
showing sufficient hybridization efficiency (majority of nuclei with signals) were
considered informative and were scored by two reviewers. Non-neoplastic liver
specimens served as the controls. Deletion for IGFBP7 was subsequently
defined by an IGFBP7: CEP4 ratio of <0.73 (mean ± 3 standard deviations in
non-neoplastic controls).
Immunohistochemistry: Immunohistochemistry in tumor sections and in
TMA was performed as described (3). The primary antibodies were anti-IGFBP7
(1:100; mouse monoclonal; R&D), anti-Ki-67 (1:200; mouse monoclonal; BD
Biosciences) and anti-CD31 (1:200, mouse monoclonal, Dako). Normal liver and
matched HCC sections were also stained with anti-AEG-1 antibody (1:500;
chicken polyclonal; in-house). The signals were developed by avidin-biotinperoxidase complexes with a DAB substrate solution (Vector laboratories).
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Images were analyzed using an Olympus microscope.
Immunofluorescence and Western blot analyses: Immunofluorescence
and Western blot analyses were performed as described (3). The primary
antibody was Anti-γ-H2AX antibody (mouse monoclonal; 1:500; Millipore) was
used for Immunofluoresce and the secondary antibody was Alexa488conjugated anti-mouse IgG (1:400; Molecular Probes). Slides were mounted in
VectaShield fluorescence mounting medium containing 4,6 -diamidino-2phenylindole (Vector Laboratories). Images were analyzed using a Zeiss
confocal laser scanning microscope. The following primary antibodies were used
for Western blot: anti-p-IGF-IR (Tyr1161; rabbit polyclonal; 1:250; Santa Cruz
Biotech), anti-IGF-IR (mouse monoclonal; 1:250; Santa Cruz) anti-p-ERK (rabbit
polyclonal; 1:2,000; Cell Signaling Technology), anti-ERK (rabbit polyclonal;
1:2,000; Cell Signaling), anti-p-AKT (Ser473; rabbit polyclonal; 1:1,000; Cell
Signaling), anti-AKT (rabbit polyclonal; 1:1,000; Cell Signaling), anti-ATR (rabbit,
1:1000; Cell Signaling), anti-p-ATR (Serine 428, rabbit, 1:1000; Cell Signaling),
anti-ATM (rabbit, 1:1000; Cell Signaling), anti-p-ATM (Serine 1981, mouse,
1:1000, novus biologicals), anti-CHK1 (rabbit, 1:1000; Cell Signaling), anti-pCHK1 (Serine 345, rabbit, 1:1000; Cell Signaling), anti-CHK2 (rabbit, 1:1000; Cell
Signaling), anti-p-CHK2 (Threonine 68, rabbit, 1:1000; Cell Signaling), anti-Rb
(mouse, 1:1000; Cell Signaling), anti-p-Rb (Serine 795, rabbit, 1:1000; Cell
Signaling), anti-p53 (rabbit, 1:1000; Cell Signaling), anti-p-p53 (Serine 15, rabbit,
1:1000, Cell Signaling), anti-p38 (rabbit, 1:1000; Cell Signaling), anti-pp38(Thr180/Tyr182, rabbit, 1:1000; Cell Signaling), anti-cyclinD1 (rabbit, 1:1000;
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Cell Signaling) and EF1-α as loading control (mouse monoclonal; 1:1000;
Millipore).
Enzyme-linked immunosorbent analysis (ELISA): The recombinant
IGFBP7 protein used as standard was obtained from R&D (catalog #1334-B7).
The wells of a 96-well plate were coated with the standard or with conditioned
media (100 µl) overnight at 4°C. The wells were washed 4 times with PBS and
then blocked with 5% non-fat milk in PBS for 1 h. Following another PBS wash
anti-IGFBP7 antibody (1:1000) was added and incubated overnight at 4°C
without shaking. After another 4 times PBS wash anti-mouse secondary antibody
(1:1000) was added and incubated at room temperature for 2 h with gentle
shaking. The wells were washed with PBS 4 times and 100 µl Glo Substrate
Reagent (R&D, DY993) was added to each well for 15 min and the reaction was
stopped by adding 100 µl Stop Solution (R&D, DY994). The plate was read at
560nm using a multiplate reader (Turner Biosystems).
Assay for Senescence Associated β-galactosidase (SA-β-gal) activity:
Cells were cultured for six days and SA-β-gal-positive cells were detected using
Senescence Detection Kit (Biovision) according to the manufacturer’s protocol
that follows the original method of detection (29).
Total RNA extraction and real time PCR assay: Total RNA was extracted
using Qiagen miRNAeasy mini kit (Qiagen). Real time PCR was performed using
an ABI 7900 fast real time PCR system and Taqman gene expression assays for
IGFBP7 and GAPDH according to the manufacturer’s protocol (Applied
Biosystems).
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Immunoprecipitation: Cell lysate were collected in lysis buffer from cell
signaling plus protease inhibitor (Roche #11 836 145 001) and phosphatase
inhibitor (Roche # 04 906 845 001) after PBS wash. The lysate was centrifuged
for 10 minutes at 14,000 X g, 4°C and and the supernatant was transferred to a
new tube.
Nude mice xenograft studies: QGY-luc cells (1X106) were
subcutaneously implanted in both flanks of athymic nude mice. After the
establishment of the tumors (~100 mm3), requiring ~1 week, intratumoral
injection of Ad.vector or Ad.IGFBP7 was administered only to the tumors on the
left flank leaving the right-flank tumors untreated. A total of five injections (1X109
vp/injection) were given over a period of two weeks and the animals were
sacrificed two weeks after the last injection. Tumor volume was measured with
calipers using the formula: Volume=(smaller diameter)2 x larger diameter / 2.
Orthotopic xenograft studies in nude mice: QGY-luc cells (QGY-7703
cells stably expressing luciferase) were orthotopically implanted by intrahepatic
injection in athymic nude mice (6-8 weeks of age). Mice were placed into a
plexiglass chamber for induction of anesthesia with 2% isoflurane and 2 liters/min
oxygen flow for a mouse of 25 g body weight. After anesthetization, animals were
transferred onto a Styrofoam pad and anesthesia was maintained by isoflurane
inhalation through a suitable mouthpiece. The mouse was placed in the left
lateral decubitus position and the skin was disinfected with betadine/ethanol
scrub. A small skin and muscle incision (about 0.5-1 cm long) was made
longitudinally (parallel to the spine) in the right flank to expose the liver. The liver
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was retracted and using a 30G needle 1 X 106 cells in 0.1 ml PBS was injected
into the parenchyma of the liver. A visible pale wheal indicated a successful
injection. The needle was retracted and a Q-tip was placed over the injection site
for 30 seconds to prevent bleeding and spillage of material. The liver was
returned to the peritoneal cavity. The peritoneum was closed with a 5-0 suture
and the skin was closed with wound clips. After closing the abdomen the skin
was wiped surrounding the suture with betadine and the animal was placed on a
warming pad for recovery. Tumor growth was monitored by bioluminescence
imaging (BLI) with a Xenogen IVIS imager once a week. The animals were
anesthetized and given intraperitoneal injection of 150mg/kg luciferin and light
emitted from each tumor was determined by a Xenogen system with CCD
camera with an integration time of 1 min. Luminescence measurements were
analyzed using Living Image software (version 2.50.1; Xenogen). One week after
implantation, when the tumor was well established, the mice were treated with
intravenous injections of Ad.vector or Ad.IGFBP7 at a dose of 1X109 vp/injection.
A total of five injections were given over a period of two weeks and the animals
were sacrificed two weeks after the last injection. Two lobes of liver were sliced
into a total of 4-6 strips and embedded in paraffin. For each mouse, 10 sections
at 30-50µm distance were H&E stained and microscopically analysed for
metastases. Metastatic lesions were classified in micro, small and large, and
burden was calculated by the sum of all metastatic lesions multiplied 1x (micro),
2x (small) and 3x (large).
Chicken chorioallantoic membrane (CAM) assay: Cells were seeded on
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the CAM surface of 9-day-old chick embryos according to established protocols
(30). One week after inoculation, the neovasculature was examined and
photographed. Angiogenesis was quantified by counting the blood vessel branch
points under a stereomicroscope. The angiogenic index was calculated by
subtracting the number of branch points from the branching in the control group.
Capillary-like tube formation assay. The formation of tube-like structures
by HUVECs on Matrigel (Chemicon) was performed as previously described (31).
HUVECs were cultured 4 hours in conditioned media from Control-2, IGFBP7-11
and IGFBP7-12 clones. The degree of network formation was quantified using an
Image analyzer (National Institutes of Health Image).
Ad. IGFBP7 virus Generation and infection protocol: Ad.IGFBP7 was
generated in Ad.5/3 backbone in which the fiber knob of Ad5 was replaced by
that of Ad3. Ad.5/3 expressing luciferase (Ad.5/3-Luc1) was previously
generated. The genome of Ad.IGFBP7 was generated by homologous DNA
recombination in Escherichia coli between linearized plasmid pShCMV-IGFBP7
(shuttle vector containing IGFBP7 open reading frame under the control of CMV
promoter) and BstBI- digested genomic DNA of Ad.5/3-Luc1 vector. The resultant
pAd.IGFBP7 plasmid, containing the Ad.5 genome encoding the IGFBP7 gene in
place of the early viral E1 region and the recombinant F5/3 fiber gene, was
selected with kanamycin. Ad.IGFBP7 was rescued by transfecting HEK-293 cells
with pAd.IGFBP7 plasmid DNA cleaved with PacI to release the viral inverted
terminal repeats. The viruses were titered by standard plaque assay. Ad.IGFBP7
was manufactured and formulated in phosphate-buffered saline (PBS). The
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vector titer was determined by means of a validated, quantitative real-time
polymerase- chain-reaction (qPCR) assay. According to the cell numbers and
virus vesicle particles (100vp per cell to 1000vp per cell) the adenovirus was
diluted with the basic DMEM media (serum and antibiotics free) and mixed well.
The volume of the adenovirus containing medium was 100ul each well for 24 well
plates, 500ul for 6cm dishes and 2 ml for 10cm dishes. After adding the medium,
the dishes were gently rotated every 15 minutes for 2 hours followed by addition
of complete DMEM media incubation until collection (10% fetus bovine serum,
ciprofloxacin 10ug/ml, streptomycin 50ug/ml and penicillin 50 units/ml P4458).
Cell cycle analysis: 1 million cells were plated in 10cm dish the day before
and next day cells were synchronized in G1 phase by culturing in 0.5% FBS
DMEM medium for 48 hours. After synchronization, the cells were infected with
Ad.vec (control empty adenovirus) or Ad.IGFBP7. The time point zero to collect
cells was after 48 hours synchronization. All the cells were collected at 0, 6, 12,
24, 36, 48, 72 and 96 hours time point after infection. The cell pellets were
centrifuged and washed by ice-cold PBS twice and then the pellets were
resuspended in 200ul ice-cold PBS and added to 5ml ice- cold 70% Ethanol
solution. The samples were kept at -20 °C until analysis. Before the analysis, the
cell were centrifuged at 2000 RPM for 10 minutes and washed in PBS twice. The
pellets were resuspended in 500ul PBS with Ribonuclease A (1ug/ml) and
incubate in 37°c for 30 minutes. After that procedure 500ul PBS containing
Propidium Iodide (100ug/ml) was added to the samples and incubated at 37°c for
30 minutes in dark. The samples were analyzed by FACS cell cycle following
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manufacturer protocol.
Baculovirus system and purification of recombinant IGFBP7 protein:
IGFBP7 (NM_001553) human cDNA clone was obtained from Origene
Technologies, Inc (Rockville, MD) and cloned pFAST HT B vector according to
the Bac-to-Bac® Baculovirus Expression System manufacturer protocol (Catalog
nos. 10359-016). The sequences of IGFBP7 in the vector were confirmed. Insect
SF9 cell lines (551407) obtained from BD Biosciences were cultured in Sf-900 II
SFM medium from Invitrogen (cat: 10902). Insect GeneJuice Transfection
Reagent (71259) from Novagen was used to transfect the pFAST HTB plasmids
expressing IGFBP7 into the SF9 cells in Grace’s Insect Medium (11595
invitrogen). When the cell viability was decreased by 50%, the cell pellet was
collected and the His-tagged protein was purified using BD BaculoGold 6xHis
Purification Kit (560138) following the manufacturer instruction. Purified protein
was checked by Western blot using HA antibody from Sigma and IGFBP7
antibody from R&D company.
Statistical analysis: Data were represented as the mean ± Standard Error
of Mean (S.E.M) and analyzed for statistical significance using one-way analysis
of variance (ANOVA) followed by Newman-Keuls test as a post hoc test. A p
value of < 0.05 was considered as significant.
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Chapter 1
IGFBP7 expression level in HCC patients’ samples and cell lines
Background: HCC is the 5th most common cancer worldwide and the 3rd leading
cause of cancer death. The prognosis of HCC patients is predicted not only by
underlying liver function but also by tumor stages. Patients will be treated
differently according to their cancer stages. In our study we used the Barcelona
Clinic Liver Cancer (BCLC) staging system, which includes tumor stage, liver
function, physical status and cancer-related symptoms. The early stage indicates
better prognosis and the late stage correlates with higher mortality. In the same
stage of HCC, patients with poor differentiation have worse prognosis compared
to patients with moderate differentiation. HCC cell lines are immortalized cell
generated from HCC patient tumor samples, which provide with good molecular
research platforms for our study.
Result: The identification of IGFBP7 as a tumor suppressor for breast, prostate
and colorectal cancer prompted us to analyze IGFBP7 expression profile in HCC
patients. To this end, we have analyzed by immunohistochemistry in tissue
microarrays (TMAs) containing 104 HCC samples and 9 normal adjacent liver
samples. Strong IGFBP7 immunostaining was detected in the 9 normal liver
samples (Fig. 1 and Table 1) while weak IGFBP7 staining was observed in the
HCC samples (Fig. 1 and Table 1). There was a gradual decrease in IGFBP7
expression with the stages of HCC based on the Barcelona Clinic Liver Cancer
(BCLC) staging system (Fig. 1A and Table 1). Interestingly, in each stage
IGFBP7 expression was much lower in poorly differentiated grades compared to
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moderately differentiated grades (Fig. 1A). To assess the negative correlation
between IGFBP7 expression and stages of HCC we conducted an ordinal logistic
regression with the stage of HCC as the ordinal response and IGFBP7
expression as the independent variable in the proportional odds model.
Hypothesis of association is highly significant (p value < 0.001) by Wald chisquare test (Table 1).
Loss of heterozygosity has been reported at the IGFBP7 locus (chromosome
4q12) in breast cancer (12). To examine the possibility that genomic deletion
might be the underlying mechanism of IGFBP7 downregulation in human HCC
patients, dual color fluorescence in situ hybridization (FISH) was performed on
human HCC TMAs containing 9 normal liver samples and 50 HCC samples.
Bacterial artificial chromosome (BAC)-derived test probe targeting IGFBP7
(orange color) was used along with a control probe that is specific for the
pericentromeric region of chromosome 4 (CEP4; green color). The control probe
(CEP4) provided information regarding the number of chromosome 4 present in
the cell. While no normal liver samples showed IGFBP7 deletion, 13 out of 50
(26%) HCC samples showed IGFBP7 deletion. Fig.1B shows a representative
normal cell in which two orange (IGFBP7) and two green (CEP4) dots are
observed. In the HCC cell, there are two signals for CEP4 but only one signal for
IGFBP7 indicating the deletion of one copy of the IGFBP7 gene.
We next checked IGFBP7 expression in THLE-3 cells which are normal human
hepatocytes immortalized by SV40 T/t Ag and several human HCC cell lines,
namely, HepG3, Hep3B, Huh7, SK-Hep1 and FOCUS. Compared to THLE-3
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cells IGFBP7 mRNA expression was profoundly downregulated in all the HCC
cell lines (Fig. 2A). These findings were confirmed by ELISA using conditioned
media demonstrating significant downregulation of secreted IGFBP7 protein in
human HCC cell lines, compared to THLE-3 cells (Fig. 2B). IGFBP7 was initially
identified as an AEG-1 downregulated gene by Affymetrix microarray. To confirm
this finding, we checked three different AEG-1-overexpressing clones of HepG3
cells, Hep-AEG-1-8, Hep-AEG-1-14 and Hep-AEG-1-20. As a control we used
Hep-pc-4 cells which are control hygromycin-resistant clone of HepG3 cells. In all
the three AEG-1 overexpressing clones, IGFBP7 mRNA expression was
profoundly downregulated compared to Hep-pc-4 cells (Fig. 2C). This finding was
further confirmed by immunofluorescence analysis. IGFBP7 protein expression
was significantly higher in Hep-pc-4 cells compared to Hep-AEG-1-14 cells (Fig.
2D). These findings were further corroborated in matched normal liver and HCC
samples from 18 patients by immunohistochemical analysis of AEG-1 and
IGFBP7 expression. In 13 out of these 18 patients very low to undetectable
levels of AEG-1 expression and high level of IGFBP7 expression were detected
in normal liver while significantly high level of expression of AEG-1 and low level
of expression of IGFBP7 were detected in the matched HCC samples (Fig. 2E).
No change in AEG- 1 or IGFBP7 expression was detected in the remaining 5
patients. These findings further confirm the inverse relationship between AEG-1
and IGFBP7 expression.
Discussion: Although IGFBP7 has shown tumor suppressor functions in a
number of epithelial cancers, very little is known about its anti-cancer role in
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HCC. In murine SV40-T/t Ag-induced liver cancer, IGFBP7 is silenced by
methylation, although the mechanism and consequence of this silencing has not
been dissected (32). A recent report showed that IGFBP7 is required for the
sensitivity of HCC cells towards interferon-based anti-cancer therapy (33). The
same report described the analysis of IGFBP7 in a small population of 30
patients demonstrating a significantly better post-operative overall survival in
IGFBP7-positive HCC patients compared to IGFBP7-negative patients (33). Ours
is the first report with a comprehensive analysis of IGFBP7 expression in 104
HCC patients in which we demonstrate a progressive decrease in IGFBP7
expression with advanced stages of HCC, as well as with poorer grades of
differentiation. We also document genomic deletion of IGFBP7 in 26% of HCC
patients analyzed. This is the first demonstration of IGFBP7 gene deletion in
HCC as a potential mechanism of reduced IGFBP7 expression during the
process of carcinogenesis. The decreased expression of IGFBP7 in HCC
patients samples indicates the possible tumor suppressor function which needs
to be confirmed by IGFBP7 overexpression studies.
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Figure 1. IGFBP7 is downregulated in human HCC samples. A. Analysis of
IGFBP7 expression in tissue microarray by immunohistochemistry. B.
Fluorescence In Situ Hybridization (FISH) was performed on human HCC
samples for IGFBP7 and CEP4 (probe targeting pericentromeric region of
chromosome 4). Red: IGFBP7; green: CEP4.
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Chapter 2
IGFBP7 over-expression inhibits growth of HCC cell lines in vitro and in
nude mice xenograft assay in vivo:
Background: The IGF axis plays a key role in the growth, differentiation,
proliferation and angiogenesis of mammalian cells and consists of two growth
factors (IGF-I and IGF-II), their receptors (IGF-IR and IGF-IIR) and a group of
IGFBPs (IGFBP1-7) (8). The Insulin-like Growth Factors binds to Insulin-like
Growth Factor Receptor and cause activation of downstream signals in the cells.
The Type I Insulin-like Growth Factor Receptor (IGF1R) is a transmembrane
glycoprotein of Insulin-receptor family and a tyrosine kinase receptor. The
activated IGF1R induces the intercellular substrate Insulin Receptor Substrate-1
(IRS-1) to bind to IGF1R SH2 domain and get phosphorylated (Fig. 3). Then the
IRS-1 activates PI3K-Akt and Erk MAPK kinase pathway. IGF1R can also
activate Erk through Grb2/SOS/Ras/Raf pathway. The Grb2 SH2 domain binds
IGF1R phosphotyrosine residues and gets activated. The docking protein Grb2
binds and activates SOS. Activated SOS removes the GDP from Ras and allows
Ras to bind GTP and become active. The small GTPase Ras binds to the
dephosphorylation Raf-1. Then the dephosphorylated Raf-1 undergoes
conformational change and activates MEK and subsequently Erk. Ras/Raf1/MEK/Erk cascade and angiogenesis play key role in development of HCC.
Vascular Endothelial Growth Factor (VEGF) is the key factor playing significant
roles in blood vessels formation (angiogenesis). Under hypoxic condition, Erk
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activates HIF-1 alpha and HIF-1 alpha induces VEGF gene expression by
interacting with Runx2 (34). Mutation in IGF1R, growth factors and IGF binding
proteins contributes to the carcinogenesis, tumor development and progression.
Due to its important role in cancer progression, IGF1R monoclonal antibody
Figitumunab and A12 (35) have been used to block IGF axis as a potential target
of anti-cancer therapy.
Senescence originates from Latin word senex meaning advanced in age.
Senescence involves irreversible block of cell cycle in G0/G1 phase but retaining
the intact metabolism chain for cell survival. The status is called replicative
senescence when cell enters into a post-mitotic condition. After DNA damage,
DNA mutation accumulates. The cells containing DNA mutation are potentially
cancerous. In normal condition, the checkpoint protein, like p53 and Rb, will stop
the cell cycle until the damage is repaired. However the cancer cells can break
through the senescence by upregulating telomerase activity or evading the
checkpoints monitoring. Identification of key proteins and mechanisms that
induce the replicative senescence will facilitate employment of these strategies
as potential therapy for cancer.
Results: HepG3 cells are non-tumorigenic in nude mice and stable
overexpression of AEG-1 in HepG3 cells (Hep-AEG-1-8 and Hep-AEG-1-14
clones) results in generation of highly aggressive, angiogenic and metastatic
tumors (28, 30, 36). The profound downregulation of IGFBP7 in Hep-AEG-1
clones prompted us to ask the question whether IGFBP7 downregulation is
necessary for maintaining the oncogenic phenotype conferred by AEG-1. For this
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purpose, we generated stable clones of Hep-AEG-1-14 cells expressing IGFBP7
by selection with zeocin. Zeocin-resistant clone of Hep-AEG1-14 cells (Control-2)
served as a control. Compared to Control-2 clone, IGFBP7-11 and IGFBP7-12
clones expressed significantly higher levels of IGFBP7 mRNA and protein,
detected by real-time PCR and ELISA, respectively (Fig. 4A and 4B). It should be
noted that secreted IGFBP7 level in IGFBP7-11 and IGFBP7-12 clones did not
reach the level of the parental HepG3 cells from which all these clones are
generated (please compare Fig. 2B and 4B). IGFBP7-11 and IGFBP7-12 clones
showed significantly slower growth rate when compared to Control-2 clone
analyzed by standard cell viability (MTT) and colony formation assays (Fig. 4C
and 4D, respectively). However, this growth inhibition was not profound showing
only ~27% inhibition by cell viability assay and ~23% inhibition by colony
formation assay in IGFBP7 overexpressing clones compared to Control-2 clone.
IGFBP-7 is known to induce senescence. As such induction of senescence in
Control-2, IGFBP7- 11 and IGFBP7-12 clones were analyzed by senescenceassociated β- galactosidase (SA-β- gal) assay. There was a significant increase
in the number of SA-β-gal-positive cells in IGFBP7-overexpressing clones
compared to Control-2 clone when cultured for 1 week (Fig. 5A and 5B). These
findings were confirmed by analyzing γ-H2AX foci, another marker for
senescence. There was a significant increase in γ-H2AX foci in the nuclei of
IGFBP7-11 and IGFBP7-12 clones when compared to Control-2 clone (Fig. 5C
and 5D).
The in vitro growth suppressor function of IGFBP7 was confirmed by in vivo
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assays. Control-2 and IGFBP7-11 and IGFBP7-12 cells were subcutaneously
xenografted into the flanks of athymic nude mice and tumor development was
monitored. There was a profound inhibition of growth of tumors generated from
IGFBP7-11 and IGFBP7-12 clones compared to Control-2 clone (Fig. 6). The in
vivo growth suppression effect of IGFBP7 was significantly higher than that in in
vitro assays. We reasoned that in addition to direct inhibition of growth by the
induction of senescence, IGFBP7 might interfere with tumor angiogenesis,
supported by marked downregulation of CD31 staining in IGFBP7overexpressing tumor sections (Fig. 6C). The effect of IGFBP7 in angiogenesis
was confirmed by implanting Control- 2, IGFBP7-11 and IGFBP7- 12 clones in
chicken chorioallantoic membrane (CAM) of 9-day old chick embryos. After one
week, neovascularization was examined, photographed and quantified.
Neovascularization was significantly inhibited by IGFBP7-11 and IGFBP7-12
clones, compared to Control-2 clone (Fig. 7A and 7B). These findings were
extended further by endothelial cell tube formation assay. Human umbilical vein
endothelial cells (HUVEC) were treated with conditioned media (CM) from
Control-2, IGFBP7-11 and IGFBP7-12 clones and endothelial cells tube
formation was scored (Fig. 7C and 7D). HUVEC tube formation was significantly
inhibited by CM from IGFBP7-11 and IGFBP7-12 clones compared to Control-2
clone further confirming the anti-angiogenic functions of IGFBP7. As a secreted
protein whether IGFBP7 binds Insulin-like growth factor and modulates its
receptor function in HCC is still unclear. We document that in IGFBP7-11 and 12
the activation of IGF1 receptor and its downstream Erk was decreased compared
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to Control-2 (Fig. 8). Analysis of angiogenesis array (R&D) indicated that
IGFBP7 downregulates VEGF and PDGF protein level. The result was confirmed
by ELISA in the conditioned media of the IGFBP7 overexpression clones.
Discussion: The markedly high expression of both IGFBP7 mRNA and protein
in normal immortal hepatocytes, THLE-3 cells, compared to several HCC cell
lines further reinforces a putative tumor suppressor role of IGFBP7 in HCC.
Affymetrix microarray analysis designed to probe the global gene expression
changes induced by the oncogene AEG-1 revealed profound downregulation of
IGFBP7 mRNA expression by AEG-1 (26-fold downregulation by microarray and
>10-fold downregulation by real time PCR) (3). Indeed our in vitro and in vivo
studies document that forced overexpression of IGFBP7 could effectively
abrogate the tumor-promoting functions of AEG-1. Although AEG-1 is known to
modulate the expression of a plethora of pro-tumorigenic genes and proteins as
well as altering signaling pathways, the profound inhibition of in vivo growth by
forced IGFBP7 overexpression in AEG-1-overexpressing cells suggest a major
role of IGFBP7 downregulation in mediating AEG-1 function. This notion is
further strengthened by the observation that the significantly lower level of
secreted IGFBP7 in IGFBP7-11 and IGFBP7-12 expressing clones of Hep-AEG1-14 cells, compared to the parental non-tumorigenic HepG3 cells (Fig. 2B and
3A), is sufficient to profoundly inhibit in vivo tumorigenesis induced by AEG-1
overexpression. The mechanism of IGFBP7 downregulation by AEG-1 remains
to be determined. Does AEG-1 induce hypermethylation of the IGFBP7 promoter
resulting in silencing of expression as observed in other cancer indications?
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Does AEG-1 interfere with transcription factor binding to the IGFBP7 promoter as
is observed for the c-myc promoter where AEG-1 physically interacts with the
transcription factor PLZF and prevents PLZF DNA binding (36)? Does AEG-1
enhance mRNA instability of IGFBP7? These issues are currently being
experimentally addressed to clarify the underlying molecular mechanism of
IGFBP7 suppressor function in AEG-1 overexpressing cells.
The in vitro growth inhibitory effect of IGFBP7 might be mediated by its ability to
interfere with Insulin, IGF1R signaling (Fig. 8E). We observed that the in vivo
inhibitory effect of IGFBP7 overexpression was more pronounced than the in
vitro effect. We document that inhibition of angiogenesis might be one
mechanism by which IGFBP7 indirectly abrogates tumor growth and progression.
We show for the first time that IGFBP7 overexpression results in inhibition of
neovascularization in the CAM model and microvessel density (CD31expression)
in a subcutaneous xenograft model in nude mice. We also document that
conditioned media from IGFBP7 overexpressing cells inhibits HUVEC tube
formation. Recombinant IGFBP7 inhibits VEGF-induced tube formation as well
as VEGF-downstream signaling in HUVEC (28). IGFBP7 also downregulates
VEGF expression in malignant melanoma cells (38). Thus, the combined effects
of VEGF downregulation in HCC cells and direct inhibition of endothelial cell
differentiation by IGFBP7 might mediate the anti-angiogenic effects of IGFBP7.
VEGF and PDGF are the main angiogenesis factors during cancer development
and progression and in our study we observed that IGFBP7 can downregulate
the level of sercreted VEGF and PGDF.
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We have detected that IGF1R and ERK activation and tumor angiogenesis were
inhibited in IGFBP7 overexpressed clones. One explanation of these observation
is that is IGFBP7 inhibits IGF1R activation by modulating insulin binding to the
receptor and blocks activation and expression of the downstream targets ERK,
VEGF and PDGF. In order to prove this hypothesis, the IGF1R blocking antibody
and the IGFBP7 neutralizing antibody could be introduced into the IGFBP7
overexpressed cells to check whether blocking IGF1R or IGFBP7 could modulate
IGF1R or Erk activation and angiogenesis. IGFBP7 may block activation of
IGF1R signaling pathway by binding to insulin or it may be endocytosed into the
cytoplasm or be transported into the nucleus to inhibit downstream kinases and
transcription factors. How IGFBP7 induces senescence is still unclear.
Senescence Associated Heterochromatin Foci indicates the existence of DNA
Double Stranded Break (DSB) and its related DNA damage repair response in
IGFBP7 overexpressing clones (39). It leads us to further investigate the role that
IGFBP7 plays during DNA damage response and DNA repair process.
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Figure 2. IGF1 and IGF1R network. P Massoner, M Ladurner-Rennau, I E Eder
and H Klocker. Insulin-like growth factors and insulin control a multifunctional
signalling network of significant importance in cancer.
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Figure 3. IGFBP7 is downregulated in human HCC cell lines and by AEG-1. A.
Determination of IGFBP7 mRNA expression by real-time PCR in the indicated
cells. THLE-3 is normal immortal human hepatocytes. GAPDH was used as
normalization control. B. Secreted IGFBP7 protein level in the conditioned media
of the indicated cells determined by ELISA. C. Determination of IGFBP7 mRNA
expression by real-time PCR in Hep-pc-4 (pc-4) cells and three independent
clones of HepG3 cells overexpressing AEG-1. D. Immunofluorescence detection
of IGFBP7 protein in Hep-pc-4 (pc-4) and Hep-AEG-1-14 (AEG1-14) cells. E.
Immunohistochemical analysis of AEG-1 and IGFBP7 expression in normal liver
and matched HCC from the same patient. The figure represents data from one
patient. Similar finding was observed in 13 out of 18 HCC patients. For A-C, data
represents mean ± SEM of three independent experiments.
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Figure 4. Overexpression of IGFBP7 inhibits growth of AEG-1-overexpressing
cells. Stable clones of Hep-AEG1-14 cells expressing IGFBP7 (IGFBP7-11 and
IGFBP7-12) were generated by selection with zeocin. Zeocin-resistant clone of
Hep-AEG1-14 cells (Control-2) served as a control. A. IGFBP7 mRNA
expression in the indicated cells detected by real-time PCR. B. Secreted IGFBP7
protein level in the indicated cells detected by ELISA. C. Cell viability (MTT)
assay of the indicated cells. D. Colony formation assay of the indicated cells. For
A-D, data represents mean ± SEM of three independent experiments.
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Figure 5. IGFBP7 induces senescence. A. Photomicrograph of Control-2,
IGFBP7-11 and IGFBP7-12 clones of Hep-AEG-1-14 cells stained for
senescence-associated β-galactosidase (SA-β-gal) after 1 week of culture. B.
Graphical representation of quantification of SA-β-gal positive cells. At least
1,000 cells were counted for each group. Data represents mean ± SEM of three
independent experiments. C. Photomicrograph of Control-2, IGFBP7-11 and
IGFBP7-12 clones of Hep-AEG-1-14 cells stained for γ-H2AX and counterstained
with DAPI to stain the nucleus. D. B. Graphical representation of quantification of
γ-H2AX foci/cell. At least 100 cells were scored for each group. Data represents
mean ± SEM of three independent experiments.
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Figure. 6. Overexpression of IGFBP7 inhibits AEG-1-mediated tumorigenesis in
nude mice. Subcutaneous xenografts were established in athymic nude mice
using Control-2, IGFBP7-11 and IGFBP7-12 clones of Hep-AEG-1-14 cells. A. A
representative photograph of tumor-bearing mice at the end of the study. B.
Measurement of tumor volume at the indicate time point. Data represents mean ±
SEM. C. Tumor sections were immunostained for IGFBP7, CD31 and Ki-67.

30

Figure 7. IGFBP7 inhibits angiogenesis. A. Control-2, IGFBP7-11 and IGFBP712 clones of Hep-AEG1-14 cells were implanted in chicken chorioallantoic
membrane (CAM) and neovascularization was photographed. B. Graphical
representation of new blood vessel formation in CAM when the indicated cells
were implanted. The numbers indicate percentage of new blood vessels arising
from the existing blood vessels in naïve CAM when VEGF-treated CAM was
considered as 100%. Data represents mean ± SEM. C. HUVECs were treated
with conditioned media from the indicated cells and tube formation was
photographed. D. Graphical representation of tube formation by HUVEC treated
with conditioned media from the indicated cells. The numbers indicate
percentage of tube-like structures when VEGF-treated tube formation was
considered as 100%. The data
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Figure 8. IGFBP7 inhibit IGF1R and ERK activation. Control-2, IGFBP7-11 and
IGFBP7-12 clones of Hep-AEG1-14 cells lysate were collected. Western blotting
were used to detect IGF1R, pIGF1R, ERK, pERK, AKT, pAKT expression in
Control-2, IGFBP7-11 and IGFBP7-12 clones of Hep-AEG1-14 cells. EF1 alpha
is the internal control. IGFBP7 overexpression clones show decrease activation
of IGF1R and ERK compared to control clone.
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Chapter 3
Ad.IGFBP7 induce HCC cell cycle arrest and apoptosis by overproduction
of ROS and p38MAPK activation
Ad.IGFBP7 transfection efficiency in multiple human HCC cell lines: We
have observed that overexpression of IGFBP7 in Hep-AEG-1 clones inhibited cell
growth and reduced tumor volume in athymic nude mice xeongraft model. The in
vitro studies have indicated that IGFBP7 is involved in senescence induction in
HCC and DNA damage response. In order to further investigate the molecular
mechanism of IGFBP7 action we expressed IGFBP7 in an Adeno5/3 virus
system. Adenovirus serotype 5, which is the most commonly used Adenovirus
used for gene therapy, infects human cells via Coxsackie-Adenovirus Receptors
(CAR). CAR is known to be downregulated in cancers. For this purpose a
serotype chimeric Ad (Ad.5/3) is generated in which the Ad5 virus knob is
replaced by Ad3 virus knob and which expresses IGFBP7 (Ad.IGFBP7). First we
tested the infection efficiency of Ad.IGFBP7 by QPCR and Western Blotting. A
significant increase in mRNA and protein levels of IGFBP7 compared to the
Ad.Vec infected cells was detected (Fig 9A). The produced IGFBP7 protein was
enriched in the cytoplasm of cells shown by Immunofluoresce and confirmed by
detecting IGFBP7 in cytoplasm fractions of the infected HepG3 cells by Western
Blotting (Fig. 9B). Western blotting & ELISA also confirmed IGFBP7 protein
expression upon Ad.IGFBP7 infection in Huh7, Hep3B and HepG3 cells (Fig. 10).
These results show that Ad.IGFBP7 can successfully infect HCC cell lines and
produce IGFBP7 protein.
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Ad.IGFBP7 induces cell cycle arrest in multiple human HCC cell lines:
Background: The cell cycle is a series of processes leading to cell duplication. It
is composed of G0 (quiescent phase), G1 (DNA synthesis), S (DNA replication),
G2 (synthesis for mitosis) and M phases (mitosis). During this process, there are
several checkpoints regulating entrance into next phase of cell cycle. G1
checkpoint proteins are cyclin-dependent kinases (CDKs), p53 and Rb. At the
end of G1 phase, the checkpoint protein checks the cell function and DNA
strand. Only the intact DNA and normal working cells are allowed to enter the
DNA synthesis (S phase). G2 phase is the phase after DNA synthesis. G2
checkpoint contains p53, ATM/ATR, CHK1/CHK2 proteins. G2 checkpoint protein
allows the cell to enter the mitosis and the complete cell division. DNA damage
from oxidative stress or UV radiation activates the related checkpoint protein and
induces G2/M arrest. Cell cycle checkpoints monitor and regulate cell cycle
progression. When DNA damage or incomplete DNA is detected, DNA repair
machinery is recruited and cell cycle progression is stopped until DNA repair is
done. This process is called DNA damage response. p53 is the major trigger
protein in G1/S and G2/M arrest. The cyclins and cyclin-dependent-kinases
(CDKs) are the two major regulatory complexes that control cell cycle
progression. Cyclin D binds to CDK4 and becomes CyclinD-CDK4 complex. The
CyclinD-CDK4 complex phosphorylates Rb and the p-Rb protein allows the
release and activation of E2F for cell cycle progression.
Result: HepG3, Hep3B and Huh7 cells were infected with Ad.vec or Ad.IGFBP7
and cell viability was measured by MTT assay (Fig. 11A). After Ad.IGFBP7
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infection inhibited proliferation in all three cell lines and profoundly inhibited
colony formation (Fig. 11B). The MTT assay, which evaluates cell numbers,
showed there was significant decrease in living cells under IGFBP7
overexpression in HCC cell lines (Fig. 11A). At 24, 48, 72 hours post-Ad.IGFBP7
infection (1000vp/cell) in Hep3B cells the cell number decreased by 41.77%,
66.43% and 69.74% in 1000vp/cell group compared to Ad.vec group. At 24, 48,
72 hours post-Ad.IGFBP7 infection (1000vp/cell) in HepG3 cells the cell number
decreased by 41.38%, 44.18% and 66.71% compared to the Ad.vec group. At
24, 48, 72 hours post-Ad.IGFBP7 infection (1000vp/cell) in Huh7 cells the cell
number decreased by 30.79%, 50.41% and 55.34% compared to the Ad.vec
group.
In order to gain insight into IGFBP7 growth inhibitory effects, cell cycle
progression of Hep3B, HepG3 and QGY7703 cells were monitored and recorded
after Ad.IGFBP7 virus infection. The cell cycle assay showed that in Hep3B cells,
Ad.IGFBP7 treatment resulted in a significant accumulation of cells in G2/M
phase, at the expense of a decrease in both G1 and S phase cell populations
(Fig. 12). At the time points of 0, 6, 12, 24, 36 and 48 hours after infection of
Hep3B cells, the percentage of cells in G2/M phases in Ad.vec group were as
follows: 19.3%, 22.7%, 28.4%, 22.3%, 22.2% and 20 % of total population.
Ad.IGFBP7 treatment of Hep3B cells resulted in the following levels of G2/M
accumulation 19.3%, 22.3%, 30.7%, 33.2%, 37.8% and 35.3% of total population
(Fig.12). In HepG3 cells, significant accumulation of cells in G2/M phase begins
at 48 hours after Ad.IGFBP7 treatment. In Ad.vec group G2/M cell levels were
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18%, 19.5%, 20.6%, 17%, 15.2%, 15.1% 11.8% and 8.4 % of total population at
0, 6, 12, 24, 36, 48, 72 and 96 hours post infection in Ad.IGFBP7 treatment the
G2/M phase cell levels were 18%, 19.9%, 19.6%, 17.9%, 18.5%, 17.2%, 19.7%
and 17.9 % of total population at the same time points (Fig.13). In QGY7703
cells, significant accumulation of cells in G2/M phase begins 48 hours after
infection. In Ad.vec group G2/M cell levels were 21.2%, 21.1%, 26.7%, 19.9%,
17.8%, 11.1 %, 14.5% and 14.9% of total population at 0, 6, 12, 24, 36, 48, 72
and 96 hours post-infection. In Ad.IGFBP7 infection the G2/M phase cell level
were 21.2%, 21%, 26.4%, 19.7%, 18.3%, 15.7%, 20.8% and 15.5 % of total
population at the same time points (Fig.14). The Cell Cycle Assay results indicate
that the IGFBP7 protein consistently induces G2/M arrest in HCC cell lines.
Following this cell cycle study, we further checked the expression of hallmark
proteins in cell cycle arrest (ATM, ATR, CHK1 and CHK2). Ad.IGFBP7 infection,
resulted in consistent increase expression of p-ATM, p-ATR, p-CHK1, p-CHK2
and p-p53 and decrease expression of p-RB and cyclinD (Figure. 15).

Ad.IGFBP7 induces apoptosis in multiple human HCC cell lines:
Background: Apoptosis is the programmed cell death with activation of internal
caspases, nuclear fragmentation and chromatin cleavage. Unlike necrosis,
apoptosis produces cell fragments called apoptotic bodies and it attracts
macrophages to remove the apoptotic cells by engulfing. The morphological
change in apoptotic program includes loss of plasma membrane symmetry and
flip of phospholipid phosphatidylserine (PS). The Annexin V with high binding
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affinity to phospholipid phosphatidylserine is used to detect apoptosis. Another
important morphological feature of apoptosis is internucleosomal cleavage of
DNA. The cleaved form of Poly ADP Ribose-polymerase (PARP) is the final
target of apoptosis and used as an apoptosis marker in Western Blotting. When
PARP senses the Single Stranded-Break of DNA (SSB), its PAR chain recruits
DNA ligase, DNA polymerase and scaffold proteins to repair the nick on the
chromosome. The activated Caspase enzyme cleaves the PAR sequence to
block repairing and the inactivated PARP depletes the ATP of the cell which
induces cell death. Cell apoptosis induced by IGFBP7 plasmid transfection was
reported in thyroid cancer cell lines (40) and IGFBP7 recombinant protein
induces apoptosis in melanoma cells (18).
Result: In order to find out whether the cell death is apoptosis rather than
necrosis, we checked cleaved PARP in the cell lysates. Poly ADP-Ribose
Polymerase (PARP) is the direct target of caspases during apoptosis and more
cleavage form of PARP can be detected as apoptosis becomes more prominent.
After overexpression of IGFBP7 in HCC cell lines we detected increased
expression of cleavage form of Poly ADP-Ribose Polymerase in a time and dosedependent manner. We regarded the time at which PARP cleavage was detected
as the initiation time of apoptosis as observed by MTT assays after infection and
it was correlated with the time point cell number decreased by MTT. Clearly we
see different initiation times in three HCC cell lines which in Hep3B cells
apoptosis begins after 24 hours, HepG3 apoptosis begin after 48 hours infection
and Huh7 cells apoptosis begin 72 hours after Ad.IGFBP7 infection (Fig.16B).
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Ad.IGFBP7 induced apoptosis was confirmed by Annexin V staining in FACS
(Fig. 16A). 72 hours post-Ad.IGFBP7 infection, HepG3 apoptotic cells increased
by 18% compared to Ad.vec group. 72 hours post-Ad.IGFBP7 infection, Huh7
apoptotic cells increased by 10.7% compared to Ad.vec group. 72 hours postAd.IGFBP7 infection, Hep3B apoptotic cells increased by 25% compared to
Ad.vec group (Fig. 16A).

Ad.IGFBP7 induces overproduction of Reactive Oxygen Species (ROS) and
activation of p38MAPK kinase:
Backgroud: DNA is the double strand helix composed of Deoxyribonucleic Acid
that maintains the integrity of genome. The semi-conservative replication and
proof reading systems allow the high fidelity of DNA replication process. DNA
damage is the major factor which impacts delicate DNA replication by DNA
polymerase (41). The most common DNA damage is oxidation and the
conversion of guanine to 8-oxo-guanine is one of the most common (41). When
DNA damage is monitored during DNA replication process, cell cycle is blocked
until DNA repair is finished. The Reactive Oxygen Species (ROS) is the major
factor inducing oxidative stress under physiological conditions. ROS refers to the
chemically active molecules containing oxygen produced during normal oxidative
phosphorylation in mitochondria. Under normal conditions, electrons are
transferred along the electron transport chain and undergo an oxidation-reduction
reaction. The final destination of electrons is oxygen and then the oxygen is
reduced to water. Superoxide O2 – is produced when oxygen is incompletely
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reduced. The protonated form of superoxide can trigger lipid peroxidation. During
cell stress, there is increased production of ROS from mitochondria respiratory
chain as well as increase leakage of electrons (42). The active chemical oxygen
containing electron components damage cell components and induces DNA
damage, genotoxic stress (43), cell cycle arrest (44) and apoptosis (45). ROS
makes nicks on nucleobases and sugar backbones (46). N-Acetylcysteine (NAC)
is a pharmacological reagent containing thiol groups which provides antioxidant
effect and is used to prevent oxidative stress damage in in-vitro experiments.
During the DNA damage response, ATM, ATR, CHK1 and CHK2 become
activated. Ataxia telangiectasia mutated (ATM) (47) is a serine/threonine kinase
which monitors the DNA double strand break (DSB). Activated ATM can induce
cell cycle arrest and apoptosis by phosphorylating CHK2 and H2AX (48). ATR,
the ataxia telangiectasia and Rad3-related protein (49) is another DNA damage
sensor. Persistent existence of single stranded DNA will activate ATR further
phosphorylating CHK1 (49). The presence of the phosphorylated forms of ATM,
ATR, CHK1 and CHK2 may indicate the existence of DNA damage response.
p38 MAPK is Mitogen-Activated Protein Kinase that is triggered by stress stimuli
and growth factor. p38 MAPK phosphorylates and activates p53/p21CIP1/WAF1
which drives G1 and G2/M arrest (50, 51). Additionally, p38MAPK is involved in
cell differentiation and the ROS induced apoptosis in HCC (52). DNA damageinducible transcript 3 (DTIT3), also called CHOP, is involved in endoplasmic
reticulum stress and apoptosis promotion. The p38MAPK kinase can activate
CHOP and suppress the downstream survivin to induce apoptosis of hepatocytes
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(53).
Result: In order to find out what triggers apoptosis in HCC after IGFBP7 protein
overproduction, we checked several possible apoptosis pathways and found
ROS was the primary pathway activated. After Ad.IGFBP7 infection we observed
significant increased production of superoxide (reactive oxygen species) in
Hep3B, HepG3, Huh7 and QGY7703 cells (Fig. 17). 48 hours after Ad.IGFBP7
infection the superoxide levels increased by 24.5%, 16%, 10% and 19% in
Hep3B, HepG3, Huh7 and QGY7703 cells compared to control. 72 hours after
Ad.IGFBP7 infection the superoxide level increased by 49%, 56%, 45% and 45%
in Hep3B, HepG3, Huh7 and QGY7703 cells compared to control. The change
was significant and the superoxide induced cell death could be rescued by
adding the N-Acetylcysteine as monitored by MTT assay. Data collected from the
MTT assay suggest that in Hep3B cells 5mM NAC can increase the cell numbers
by 38% 48 hours after Ad.IGFBP7 infection compared to Ad.vec. In HepG3 cells
5mM NAC can increase 28% of cell numbers at 24 hours after infection. In Huh7
cells 5mM NAC can increase cell numbers by 35% at 48 hours and 10mM NAC
can increase cell number by 22% at 24 hours after infection (Fig. 18). From the
data our conclusion is that Ad.IGFBP7 induced cell death ROS production.
One of the very important signals involved in DNA damage is p38MAPK.
After infection of HCC cells by Ad.IGFPB7, we detected consistent p38MAPK
activation in HepG3, Hep3B and Huh7 cell lines (Fig. 15). In order to investigate
the role of p38 MAPK during apoptosis by Ad.IGFBP7, we added p38MAPK
inhibitor, SB203580 after Ad.IGFBP7 infection. The MTT results indicated that in
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Hep3B cells 2uM SB at 24 hours after Ad.IGFBP7 infection increased cell
numbers by 18%, in HepG3 cells 1uM SB increased cell numbers by 12% at 24
hours and 35% at 48 hours after infection, in Huh7 cells 1uM SB increased cell
numbers by 21% 48 hours after infection and in QGY7703 cells 1uM SB
increased cell numbers by 22% at 48 hours after infection. This data leads to the
conclusion that IGFBP7 induces cell death by activation of p38MAPK pathway
(Fig.19).
Discussion: In IGFBP7 overexpressed HepG3-AEG- 1-14 cells we have
detected SAHF by γH2AX staining. The increase of γH2AX foci indicates a DNA
damage response and DNA repair. It leads us to connect IGFBP7 with the DNA
Double Strand Break damage repair and cell stress. IGFBP7 delivered by
Adenovirus showed significant cell cycle arrest (Fig.12-14) and apoptosis
induction in HCC cell lines (Fig. 16). Our studies show for the first time that
Ad.IGFBP7 promotes production of superoxide (ROS). The generated ROS
produces DNA damage and activation of ATM, ATR, CHK1, CHK2 and p38
MAPK. ROS activates p38 MAPK and induces both cell cycle arrest and
apoptosis (50, 51). NAC and SB203580 are used in this study to partially block
ROS and p38MAPK effect on apoptosis in the first 48 hours after Ad.IGFBP7
infection. The partial rescue by these drugs could be due to only one dose
treated right after Ad.IGFBP7 infection and it is possible that delivering fresh drug
every day could fully rescue the cells after infection. IGFBP7 is a downstream
target of p53 and p53 increases IGFBP7 expression by binding to the p53
response element on intron 1 (19, 54). In our system, HepG3 and Huh7 cells
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have increased phosphorylation of p53 while Hep3B cells are p53 null. So
IGFBP7 induced cell cycle arrest and apoptosis may go through both the p53
dependent and independent pathways (55). The p53 dependent pathway follows
the classic p53-ATR-CHK1 kinase cascade. The independent pathway may
involve the DNA synthesis and repair enzymes. Another important tumor
suppressor protein Retinoblasoma protein is affected by IGFBP7. After
Ad.IGFBP7 infection, the level of p-RB is down-regulated and the total RB level
gets up-regulated. The RB-ATR-CHK1 is another important cycle control
pathway by IGFBP7. The RB protein works as a pocket protein which binds
transcription factor E2F family and controls the G1/S cell cycle. RB protein is also
involved in G2/M cycle control (56). IGFBP7 increased expression of RB and
decreased level of p-RB. However we did not observe significant cell cycle arrest
in G1/S phase. In our system the total increased RB protein level may come from
increased transcription of mRNA or decreased degradation. It is possible that
IGFBP7 may be involved in the process body (P body) to modulate mRNA
stability. It is also possible that IGFBP7 might specifically accelerate the
degradation of some mRNA while stabilizing some mRNA like RB. In order to
further investigate the mechanism of increased RB and decreased p-RB level we
could add the transcription and translation inhibitor to the infected cells and use
QPCR to check mRNA level changes. In addition RB ubiquitination assay can be
used to test the delayed degradation of RB in vitro.
We detected DNA damage response partially from overproduction of superoxide
and NAC can partially rescue the cell death. IGFBP7 induced apoptotic events
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might activate membrane attack complex to form pores on the outside membrane
of mitochondria or IGFBP7 might modulate enzyme activity involved in ROS
production so that the net result is production of ROS. Our observations lead to
further question: How IGFBP7 promotes overproduction or excess leakage of
active oxygen electron from mitochondria? Does DNA damage result from
IGFBP7 directly nick the DNA strands or by exposure to superoxide? Does
IGFBP7 facilitate the release of endonuclease or exonuclease from mitochondria
to interact on DNA strands (57)? How does IGFBP7 accelerate the degradation
of mRNA? Are the p38 MAPK, Rb-ATM-CHK2 and ATR-CHK1-p53 activation
separate events or serial sequences following ROS induced by IGFBP7? All of
these questions are still under investigation.
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Figure 9. Ad.IGFBP7 infection efficiency and IGFBP7 localization. A. QPCR of
IGFBP7 in Ad.IGFBP7 infected HCC cell lines compare to the Ad.vec group. B.
Western Blotting of IGFBP7 in cytoplasm and nuclear fraction of HepG3 cells
infected with Ad.IGFBP7. C. Immunofluoresce staining of IGFBP7 in HepG3 cells
infected with Ad.IGFBP7.
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Figure 10. Ad.IGFBP7 generates IGFBP7 protein. A. Huh7, Hep3B and HepG3
cells were either uninfected (Control) or infected with Ad.vec or Ad.IGFBP7 at an
m.o.i. of 1,000 vp/cell. Cells in the Control and Ad.vec groups were harvested 3
days post-infection while those in Ad.IGFBP7 group were harvested 1, 2 and 3
days post-infection. The lysates were subjected to Western blot analyses using
anti-HA antibody. EF1-a was used as loading control. B. Huh7, Hep3B and
HepG3 cells were infected with Ad.vec or Ad.IGFBP7 at an m.o.i. of 1,000
vp/cell. Conditioned media (CM) were collected 24 and 48 h post-infection and
subjected to IGFBP7 detection by ELISA. The data represent mean ± SEM. #:
p<0.05; *: p<0.01.
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Figure 11. Ad.IGFBP7 inhibits proliferation of human HCC cells. A. Huh7, Hep3B
and HepG3 cells were either uninfected (Control) or infected with Ad.vec (1,000
vp/cell) or Ad.IGFBP7 (100, 500 or 1,000 vp/cell). Cell viability was detected by
standard MTT assay 1, 2 and 3 days post-infection. B. Huh7, Hep3B and HepG3
cells were either uninfected (Control) or infected with Ad.vec (1,000 vp/cell) or
Ad.IGFBP7 (100, or 1,000 vp/cell) and subjected to colony formation assay.
Colonies were scored after two weeks. The data represent mean ± SEM. #:
p<0.05; *: p<0.01.
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Figure 12. IGFBP7 induces G2/M arrest in Hep3B cells. Hep3B cells were
synchronized by culturing for 48 hours in 0.5% FBS medium. After
synchronization cells were infected by Ad.IGFBP7 and collected at 6 hours, 12
hours, 24 hours, 36 hours and 48 hours after infection. FACS was used to
analyze cell cycle.
47

Figure 13. IGFBP7 induces G2/M arrest in HepG3 cells. HepG3 cells were
synchronized by culturing for 48 hours in 0.5% FBS medium. After
synchronization cells were infected by Ad.IGFBP7 and collected at 6 hours, 12
hours, 48 hours, 72 hours and 96 hours after infection. FACS was used to
analyze cell cycle.
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Figure 14. IGFBP7 induces G2/M arrest in QGY-7703 cells. QGY-7703 cells
were synchronized by culturing for 48 hours in 0.5% FBS medium. After
synchronization cells were infected by Ad.IGFBP7 and collected at 6 hours, 12
hours, 24 hours, 48 hours and 72 hours after infection. FACS was used to
analyze cell cycle.
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Figure 15. IGFBP7 activates ATM, ATR, CHK1, CHK2 and p38 in Huh7, HepG3
and Hep3B cells. The cell lysates were collected at 24 hours and 48 hours after
Ad IGFBP7 infection (1000vp/cell). Western blotting was performed using
antibodies against ATM, p-ATM, ATR, p-ATR (Ser428, #2853 cell signaling),
CHK1, p-CHK1, CHK2, p-CHK2, p38, p-p38, Rb, p-Rb, cyclinD1 and p53. EF1
alpha antibody was used as a loading control.

50

Figure 16. Ad.IGFBP7 induces apoptosis in human HCC cells. A. Huh7, Hep3B
and HepG3 cells were infected with Ad.vec or Ad.IGFBP7 at an m.o.i. of 1,000
vp/cell. Apoptosis was detected by Annexin V staining followed by flow cytometry
1, 2 and 3 days post-infection. The data represent mean ± SEM; *: p<0.01. B.
Huh7, Hep3B and HepG3 cells were either uninfected (Control) or infected with
Ad.vec or Ad.IGFBP7 at an m.o.i. of 1,000 vp/cell. Cells in the Control and
Ad.vec groups were harvested 3 days post-infection while those in Ad.IGFBP7
group were harvested 1, 2 and 3 days post-infection. The lysates were subjected
to Western blot analyses using anti-PARP antibody. EF1-a was used as loading
control.
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Figure 17. IGFBP7 upregulates production of Reactive Oxygen Species in QGY7703, Huh7, Hep3B and HepG3 cells. The figures show the ratio of Superoxide
level within the cells after 24 hours, 48 hours and 72 hours infection with
Ad.IGFBP7 compared to the Ad.vec. The mean and standard deviation are
provided. *: p<0.05.
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Figure 18. N-acetylcysteine (NAC) can partially prevent the cell apoptosis
induced by IGFBP7. The black column represents the non NAC treatment group,
the grey column represents the 5mM NAC treated group and the white column
represents the 10mM NAC treated group. The mean and stardard deviation are
provided. *: p<0.05.
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Figure 19. p38 MAPK inhibitor SB203580 can partially rescue the cell death
induced by IGFPB7. This figure uses MTT assay to test the cell viability. The
black column represent the non SB treatment group. The grey column represents
the 1um SB treatment group. The white column represents the 2um SB treatment
group. The mean and standard deviation. *: p<0.05)
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Chapter 4
Ad.IGFBP7 inhibits tumor growth in mouse tumor models:
Background: HCC is a highly aggressive cancer that metastasizes both
intrahepatically and extrahepatically. We have observed that IGFBP7 inhibits the
subcutaneous tumor growth in nude mice. To establish IGFBP7 as a potential
therapeutic, we tested the effect of IGFBP7 in the mouse orthotopic HCC tumor
model. The Orthotopic animal model allows for tumor growth in the primary tissue
of its origin and it provides a strong clinically relevant screening platform for gene
therapy. In order to monitor the tumor growth in vivo, we established QGY-luc
cells, which are QGY-7703 HCC cell lines expressing luciferase reporter gene.
Luciferase substrate luciferin is first injected intraperitoneally and then the
reaction product oxyluciferin is made when luciferin is metabolized by
luciferease. The bioluminescence can be detected and quantified by the IVIS
bioluminescence imaging system. The strength and surface area of
bioluminescence indicate the depth and size of the tumor in the liver. The yolk
sac and the liver produce alpha Fetal-Protein (AFP) during fetal development
phase. In normal adult the level of AFP is lower than 10ng/ml and increase in
AFP level more than 500ng/ml strongly indicates Hepatocellular carcinoma, germ
cell tumors and metastatic liver cancer.

Ad. IGFBP7 inhibits growth and metastasis of orthopedic tumor in nude
mice: We performed orthotopic implantation of QGY-luc cells in the livers of
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nude mice and monitored tumor development by bioluminescence imaging (BLI)
(Fig.20A). One week after implantation, when the tumor is well established, the
mice were treated with intravenous injections of Ad.vec or Ad.IGFBP7 at a dose
of 1X109 vp/injection. A total of five injections were given over a period of two
weeks and the animals were sacrificed two weeks after the last injection. In
Ad.vec-treated group tumors gradually increased in size as reflected by a marked
increase in bioluminescence intensity at the end of the experiment (Fig.20A).
Conversely, in the Ad.IGFBP7-treated animals, the tumors did not at all grow in
size. Rather in majority of the animals almost no bioluminescence was detected
at the end of the experiment (Fig.20A). Macroscopically, in the Ad.vec-treated
group, large tumors were observed in the liver, while the livers of the Ad.IGFBP7treated group preserved their normal morphology and very small tell-tale signs of
the tumor could be observed (Fig.20C). Microscopic analysis of the liver revealed
significant intrahepatic metastasis in Ad.vec-treated group, while in the
Ad.IGFBP7-treated group little to no intrahepatic metastasis was detected
(Fig.20D). Analysis of mouse serum showed a marked decrease in human alphafetoprotein level in Ad.IGFBP7-treated mice compared to Ad.vec-treated mice
(Fig.20E).
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Ad. IGFBP7 inhibits growth of subcutaneous tumors both on the injection
side and distant side in nude mice: In order to analyze IGFBP7 suitability as a
secreted protein and ability to inhibit tumor formation at distant sites, we
implanted QGY-luc cells subcutaneously on both flanks of nude mice (Fig.21A).
After the establishment of the tumors, requiring 1 week, intratumoral injection of
Ad.vec or Ad.IGFBP7 was administered only to the tumors on the left flank
leaving the right-flank tumors untreated. A total of five injections (1X109
vp/injection) were given over a period of two weeks and the animals were
sacrificed two weeks after the last injection. In Ad.vec-treated group there was
gradual increase in both the left- and right-sided tumors (Fig.21B, C). In the
majority of the animals, there was complete dissolution of the tumors of the leftsided injected tumors. More importantly, there was also a significant inhibition of
growth of the right-sided uninjected tumors. Ad.IGFBP7 inhibited subcutaneous
tumor growth on both sides of the nude mice. Immunohistochemistry staining of
tumor slides on both sides in Ad.vec treated group and Ad.IGFBP7 treated
groups were studied. H&E staining showed universal purple stained by
hematoxylin and decrease staining of nuclei indicating necrosis in both the left
and right sided tumors treated with Ad.IGFBP7 compared to Ad.vec treated
groups. IGFBP7 protein expressions were detected by IHC in the left sides of
tumors which were directly treated with Ad.IGFBP7. Proliferation marker Ki67
expression was significant decreased in both the left and right sided tumors of
the Ad.IGFBP7 treated groups (Fig.21D). Additionally decreased staining of
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CD31 was observed in Ad.IGFBP7 group indicating inhibition of angiogenesis.
These finding indicate that Ad.IGFBP7 induced tumor necrosis and inhibited
tumor cell proliferation on the injection sides of tumor and the secreted IGFBP7
might enter the circulation and inhibit tumor on the other side by inhibiting
proliferation and angiogenesis.
Discussion: IGFBP7 delivered by adenovirus significantly inhibited the tumor
growth at the injected side. The anti-angiogenesis effect induced necrosis in the
center of the tumor on the injection side. We observed that tumors were inhibited
not only on the injection side but also on the uninjected side. This finding
indicated that IGFBP7, as a secreted protein worked both in autocrine and
paracrine modes. IGFBP7 entered into the circulation and exhibited action at
distant sites. What is the threshold for IGFBP7 to initiate its tumor inhibition effect
is still unclear and need to be evaluated by more patients’ serum samples by
ELSA. Secreted IGFBP7 might also modulate the function of the immune system
generating an anti-tumor immune response, a hypothesis that remains to be
experimentally tested. Our preliminary findings document that recombinant
IGFBP7 efficiently inhibits growth of human HCC cells without affecting normal
THLE-3 cells. Treatment of the tumor directly by the purified recombinant
IGFBP7 protein can test the therapeutic effect in vivo.
In summary, we identify IGFBP7 as a unique and novel putative tumor
suppressor for HCC. IGFBP7 can induce ROS production induce a DNA damage
response triggering cell cycle arrest and apoptosis by activation p53, Rb, ATM,
ATR, CHK1, CHK2 and p38MAPK. In this context, IGFBP7 might be developed
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as a potential anti-HCC therapy. Studies are ongoing to develop targeted and
effective delivery systems for administering IGFBP7 to HCC patients.
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Figure 20. Ad.IGFBP7 inhibits orthotopic human HCC xenografts and intrahepatic metastasis. QGY-luc cells were orthotopically implanted by intrahepatic
injection in athymic nude mice and treated with i.v. injections of Ad.vec or
Ad.IGFBP7. A. Bioluminescence imaging of the mice before and after treatment.
B. Quantification of photon counts from the animals. The data represent mean ±
SEM; *: p<0.01. C. Photomicrograph of the livers at the end of the study. D.
Analysis of intra-hepatic metastasis score at the end of the study. E. Analysis of
serum human a-fetoprotein (AFP) levels at the end of the study. For D and E, the
data represent mean ± SEM; *: p<0.01.
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Figure 21. Ad.IGFBP7 inhibits primary and distant tumors. Subcutaneous
xenograft athymic nude mice model were established by injection QGY7703-luc
cell clones (1X106) on both sides and treated with control Ad.Control vector and
IGFBP7 on the left flank of tumors. Figure A shows the representative photo of
tumor-bearing mice at the end of study. The left panel is control vector treated
group and the right is Ad.IGFBP7 treated group. Figure B is the measurement of
the tumor volume at week1, week2, week3 and week4 each time points. Data
indicates means±SEM. (p<0.01). Figure C demonstrate the measurement of
tumor weight of left and right sides from the mice in Ad Vector treated group and
Ad.IGFBP7 treated groups. Data indicates means±SEM. (p<0.01). D. Tumor
sections were stained with hematoxylin and eosin (H&E) or stained for IGFBP7,
Ki-67 and CD31. Asterisk (*) represents necrotic areas. Arrows indicate blood
vessels. Magnification: 400x.
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Figure 22. Hypothesis of IGFBP7 function in Hepatocellular carcinoma. In low
concentration IGFBP7 induce senescence by producing DNA double-strand
breaks. Reactive oxygen species was overproduced under high concentration of
IGFBP7 delivered by Adeno virus. The DNA damage triggered ATR, ATM, CHK1
and CHK2 activation and led to cell cycle arrest. IGFBP7 also activated p38 and
led to apoptosis of HCC cell lines. IGFBP7 inhibited the activation of IGF1
receptor and ERK. The downstream angiogenesis factor like VEGF and PDGF
were inhibited.
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